

Date: August 12, 2023

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Sandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	---

Dear Sir/Madam,

Subject: Outcome of Board Meeting

This is to inform you that the Board of Directors of the Company at its meeting held today, which commenced at 14:00 Hrs. and concluded at 19:30 Hrs., inter-alia, unanimously approved/consented/took on record the following:

1. Financial Results:

- Un-audited (Standalone and Consolidated) Financial Results of the Company for the quarter ended on June 30, 2023 along with Limited Review report thereon.

2. Annual General Meeting:

- We wish to inform you that the 13th Annual General Meeting of the Company would be held on Monday, September 25th, 2023 at 11:00 A.M. (IST) through Video Conferencing / Other Audio Visual means (VC /OAVM), in compliance with applicable circular(s)/notifications issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, inter-alia, to transact the business as set out in the Notice convening the said AGM. The details of which are as below:

Sr. No.	Particulars	Remarks / Explanation
1	Date and Time of Meeting	Monday, September 25, 2023 at 11:00 Hrs. (IST)
2	Mode of Meeting as per Regulatory Requirement	Through Video Conference / OR Other Audio-Visual Means (OAVM)
3	Record Date for Payment of Final Dividend	Friday, September 15, 2023
4	Book Closure Date	From: Saturday, September 16, 2023 To: Monday, September 25, 2023 (Both Days inclusive)
5	Dividend Declared by Board in Meeting held on	May 27, 2023
6	Final Dividend recommended for Financial Year 2023	Rs. 2.75/- (Rupees Two and Seventy Five Paise Only)

7	Contact Details of the Company	Mr. Sujoy Sudipta Bose Company Secretary and Compliance Officer Email ID: investors@krsnaa.in Contact No.: +91 20 2740 2400
---	--------------------------------	---

The dividend, once approved by the Members will be paid, subject to TDS, within 30 days from the date of declaration, to those members whose name(s) appear in Company's Register of Members and/or Register of Beneficial Owners maintained by depositories as on the aforesaid record date.

3. Appointment of Company Secretary

The Board has appointed Mr. Sujoy Sudipta Bose (ACS: A43755) as Company Secretary (Key Managerial Personnel), with effect from August 12, 2023, in its Meeting dated August 12, 2023.

The additional details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed as Annexure.

It is requested to take this intimation on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer




Annexure

Disclosure required pursuant to Regulation 30 of the Listing Regulations read with Para A of Schedule III to the Listing Regulations read with the SEBI Circular having reference no. CIR/CFD/CMD/4/2015 dated September 9 2015, with regard to change in Key Managerial Personnel is given herein under:

Appointment of Mr. Sujoy Sudipta Bose as Company Secretary

Sr. No.	Particulars	Information of such events
1.	Reason for Change viz. Appointment, Resignation, Removal, Death or Otherwise	Appointment of Mr. Sujoy Sudipta Bose (ACS: A43755) as Company Secretary (Key Managerial Personnel) of the Company.
2.	Date of Appointment / Cessation & Term of appointment	Appointed w.e.f. August 12, 2023
3.	Brief Profile	Mr. Sujoy Sudipta Bose, an Associate Member of the Institute of Company Secretaries of India (ACS No. A43755) having more than 8 years of experience in Corporate Law, Commercial Laws and Compliance.
4.	Disclosure of relationships	He is not related to any of the Directors on the Board.



Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2023

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	1,322.85	1,158.59	1,117.70	4,640.83
	Other income	42.22	59.38	46.48	194.10
	Total Income	1,365.07	1,217.97	1,164.18	4,834.93
2	Expenses				
	Cost of material consumed	277.69	256.91	119.67	741.79
	Employee benefits expense	196.01	186.33	144.05	656.27
	Finance costs	19.54	22.34	13.82	76.83
	Depreciation and amortization expense	157.35	145.97	123.62	537.82
	Fees to hospitals and others	157.53	124.56	271.01	761.63
	Other expenses	369.78	339.83	270.70	1,238.68
	Total Expenses	1,177.90	1,075.94	942.87	4,013.02
3	Profit before tax (1) - (2)	187.17	142.03	221.31	821.91
4	Tax expenses				
	Income Tax charge	38.19	21.08	48.15	149.31
	Income Tax charge relating to earlier years	(6.26)	-	-	0.52
	Deferred tax charge/(credit)	2.72	2.86	5.16	36.99
	Total tax expenses	34.65	23.94	53.31	186.82
5	Profit for the period/year (3) - (4)	152.52	118.09	168.00	635.09
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss				
	Re-measurement gains on defined benefit plans	2.16	3.35	1.17	6.89
	Income tax effect	(0.54)	(0.83)	(0.30)	(1.73)
	Total other comprehensive income for the period/year	1.62	2.52	0.87	5.16
7	Total comprehensive income for the period/year, net of tax (5+6)	154.14	120.61	168.87	640.25
8	Paid-up equity share capital (Face Value of Rs. 5/ each)	156.99	156.99	156.99	156.99
	Other equity				7,268.02
	Earnings per share (Not annualised for periods):				
	Basic (Rs.)	4.86	3.76	5.35	20.23
	Diluted (Rs.)	4.71	3.67	5.33	19.72



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

P. Bhatevara

Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune

Date: August 12, 2023

Notes to Unaudited Standalone Financial Results:

1. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 12, 2023.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
4. The numbers for quarter ended March 31, 2023 are the balancing numbers between audited number in respect of full year ended March 31, 2023 and published year to date numbers of nine month ended December 31, 2022.
5. Previous period figures have been regrouped/ rearranged wherever considered necessary.



Place: Pune
Date: August 12, 2023

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Pallavi Bhatevara
Managing Director
DIN: 03600332

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2023

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	1,395.79	1,332.26	1,128.59	4,871.23
	Other income	42.22	59.26	46.40	193.79
	Total Income	1,438.01	1,391.52	1,174.99	5,065.02
2	Expenses				
	Cost of material consumed	277.69	256.91	119.67	741.79
	Employee benefits expense	229.18	211.08	161.03	745.64
	Finance costs	19.61	22.36	13.86	76.97
	Depreciation and amortization expense	157.35	145.96	123.62	537.82
	Fees to hospitals and others	173.86	159.95	274.90	812.07
	Other expenses	401.41	359.47	295.13	1,348.72
	Total Expenses	1,259.10	1,155.73	988.21	4,263.01
3	Profit before tax (1) - (2)	178.91	235.79	186.78	802.01
4	Tax expenses				
	Income Tax charge	38.19	21.08	48.15	149.31
	Income Tax charge relating to earlier years	(6.26)	-	-	0.52
	Deferred tax charge/(credit)	0.55	25.53	(3.52)	31.07
	Total tax expenses	32.48	46.61	44.63	180.90
5	Profit for the period/year (3) - (4)	146.43	189.18	142.15	621.11
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss				
	Re-measurement gains on defined benefit plans	2.07	3.02	1.08	6.54
	Income tax effect	(0.52)	(0.76)	(0.27)	(1.65)
	Total other comprehensive income for the period/year	1.55	2.26	0.81	4.89
7	Total comprehensive income for the period/year, net of tax (5+6)	147.98	191.44	142.96	626.00
	Profit for the period/year				
	Attributable to:				
	Equity Holders of the Holding Company	146.43	189.18	142.15	621.11
	Non Controlling Interests	-	-	-	-
		146.43	189.18	142.15	621.11
	Total other comprehensive income/(loss) for the period/year				
	Attributable to:				
	Equity Holders of the Holding Company	1.55	2.26	0.81	4.89
	Non Controlling Interests	-	-	-	-
		1.55	2.26	0.81	4.89
	Total comprehensive income for the period/year				
	Attributable to:				
	Equity Holders of the Holding Company	147.98	191.44	142.96	626.00
	Non Controlling Interests	-	-	-	-
		147.98	191.44	142.96	626.00
8	Paid-up equity share capital (Face Value of Rs. 5/ each)	156.99	156.99	156.99	156.99
	Other equity				7,230.37
	Earnings per share (Not annualised for quarters):				
	Basic (Rs.)	4.66	6.03	4.53	19.78
	Diluted (Rs.)	4.52	5.88	4.51	19.29



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

P. Bhatevara

Pallavi Bhatevara
Managing Director
DIN: 03600332

Notes to Unaudited Consolidated Financial Results:

1. These unaudited Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at its meeting held on August 12, 2023.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence, no separate segment information has been furnished herewith.
4. The numbers for quarter ended March 31, 2023 are the balancing numbers between audited number in respect of full year ended March 31, 2023 and published year to date numbers of nine month ended December 31, 2022.
5. Previous period figures have been regrouped/ rearranged wherever considered necessary.



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: August 12, 2023

Independent Auditor's Review Report on unaudited Standalone financial results for the quarter of Krsnaa Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krsnaa Diagnostics Limited ('the Company') for the quarter ended June 30, 2023 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



MSKA & Associates

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

SDKhivasara

Shraddha Khivasara
Partner

Membership No.:134285

UDIN: 23134285BHBDHE2373



Place: Pune

Date: August 12, 2023

Independent Auditor's Review Report on unaudited consolidated financial results for the quarter of Krsnaa Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors Krsnaa Diagnostics Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Krsnaa Diagnostics Limited ('the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2023 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



MSKA & Associates

Chartered Accountants

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Bhatinda) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (SAS Nagar) Private Limited	Wholly Owned Subsidiary
7	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

6. We did not review the Interim financial information of Seven (7) subsidiaries included in the Statement, whose interim financial information reflects total revenues of INR 146.71 million, total (loss) after tax of INR (6.08) million and total comprehensive (loss) of INR (6.14) million, for the quarter ended June 30, 2023, as considered in the Statement. This interim financial information has been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

SD Khivasara

Shraddha Khivasara
Partner

Membership No.: 134285
UDIN: 23134285BHBDHF9711



Place: Pune
Date: August 12, 2023